Prominent Players - Cancer Immunotherapy Industry

The worldwide cancer immunotherapy market is expanding rapidly as a result of increased research and development (R&D) efforts throughout the world. Moreover, rising cancer prevalence and improved efficacy and precision of newer medicines are projected to drive market expansion. Nevertheless, key problems such as the high cost of cancer immunotherapy treatment and cancer treatment side effects are predicted. Throughout the projected period, the worldwide cancer immunotherapy market is predicted to rise due to newer medicines' increasing efficacy and precision. The high cost of cancer immunotherapy treatment, as well as the side effects of cancer treatment, are market restraints.

According to Coherent Market Insights, the global Cancer Immunotherapy Market was valued at US$ 93,407.0 Mn in 2021 and is forecast to reach a value of US$ 180,137.7 Mn by 2028 at a CAGR of 9.9% between 2022 and 2028. 

Market Leaders in the Cancer Immunotherapy Industry:

Novartis AG

The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. In January 2020, Novartis AG announced that it had completed acquisition of The Medicines Company, a pharmaceutical company. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol.

Merck & Co. Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health.  Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

F-Hoffmann La Roche

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, and internationally.  It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.

Eli Lilly and Company

The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Bayer AG

Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and other consumer healthcare products. Founded in 1863, headquartered in Germany.

AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines.  AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. In June 2020, AstraZeneca announced its collaboration with Accent Therapeutics to discover, develop, and commercialize transformative therapeutics targeting RNA-modifying proteins for the treatment of cancer.

Astellas Pharma Inc

In February 2020, Astellas Pharma Inc. and Seattle Genetics Inc. announced that the U.S.  FDA has granted Breakthrough Therapy designation for PADCEV, in combination with immune therapy pembrolizumab in First-line advanced bladder cancer.

Amgen Inc.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California. In August 2020, Amgen Inc. received the U.S. Food and Drug Administration (FDA) approval for the expansion of Kyprolis (Carfilzomib) in combination with Darzalex plus Dexamethasone in two dosing regimens for the treatment of relapsed multiple myeloma. In January 2020, Amgen Inc. and BeiGene announced strategic collaboration to expand its oncology presence in China. Moreover, Amgen Inc. collaborated with Guardant Health Inc.  and Qiagen to accelerate the molecular testing for patients with Non-small Cell Lung Cancer.

OSE Immunotherapeutics SA

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. OSE Immunotherapeutics SA was founded in 2012 and is headquartered in Nantes, France. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, ARCAGY-GINECO, Foundation FoRT, and Nantes University Hospital; and Boehringer Ingelheim, MabSilico, CKD, Servier, Veloxis Pharmaceuticals, and Chong Kun Dang Pharmaceutical Corporation. On February 2023, provides a regulatory update on the clinical development plan of Tedopi®, an immunotherapy activating tumor specific T-cells, in phase 3 in monotherapy in advanced or metastatic non-small cell lung cancer (NSCLC) after checkpoint inhibitor failure, committed in advancing the clinical development for Tedopi® as a potential new standard of care in monotherapy in second line for advanced or metastatic lung cancer patients in secondary resistance to ICI now used in first line.

Bristol- Myers Squibb Company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company was founded in 1887 and is headquartered in New York, New York.

*Defintion-

Immunotherapy is a cancer treatment that use the body's immune system to attack the illness. Immunotherapy aids the immune system in its battle against cancer. Immunotherapy improves outcomes for persons with a variety of cancers that are often misdiagnosed. Cancer immunotherapy has the potential to treat a wide range of cancers.